LGND News and Press, Ligand Pharmaceuticals Incorporated From 07/14/21

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors. Dr. Cochran is the Shriram Chair of the Department of Bioengineering at Stanford U...

COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that enrollment has been completed for its Phase ...

The FDA has accepted with priority review the BLA for Johnson & Johnson (JNJ) Janssen unit's ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.The PDUFA date is November 29, 2021.Janssen began a rolling submission of the CAR-T therapy in December.J&a...

I looked inside our U.S. small-cap Funds to see which of the major meme stocks are in our ETFs. I think I captured most of the main ones from the frenzy. Another Index that we think could be ripe for a “GameStopping” is the Russell Microcap Index, which tracks the 1,000 ...

Ligand Pharmaceuticals (NASDAQ: LGND) stock skyrocketed earlier this year. However, the short squeeze that fueled those massive gains is now over . That means that Ligand probably needs a more conventional catalyst to go on another run. The company announced its first-quarte...

Image source: The Motley Fool. Ligand Pharmaceuticals Inc (NASDAQ: LGND) Q1 2021 Earnings Call May 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcrip...

Ligand Pharmaceuticals Incorporated (LGND) Q1 2021 Earnings Conference Call May 03, 2021, 2:30 PM ET Company Participants John Higgins - Chief Executive Officer Matthew Korenberg - Executive Vice President, Finance and Chief Financial Officer Matthew Foehr - President and Chief Operating Offi...

Ligand Phaarmaceuticals (LGND) swung to a Q1 profit, helped by a ~48% year-over-year increase in sales of Captisol to $31.3M.The company said the boost in Capitol sales was in large part due to its use with Gilead's COVID-19 trteatment Veklury (remdesivir).Net income in Q1 was $18.1M ($1.05 p...

Ligand Pharmaceuticals (LGND): Q1 Non-GAAP EPS of $1.41 beats by $0.28; GAAP EPS of $1.05 beats by $0.67.Revenue of $55.15M (+66.3% Y/Y) misses by $7.85M.Ligand today affirms its guidance for 2021 total revenues to be approximately $291 million and 2021 adjusted earnings per diluted share to ...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates. Ligand management will host a conf...